Quanterix Corp Files 8-K on Financials
Ticker: QTRX · Form: 8-K · Filed: Jan 14, 2025 · CIK: 1503274
| Field | Detail |
|---|---|
| Company | Quanterix Corp (QTRX) |
| Form Type | 8-K |
| Filed Date | Jan 14, 2025 |
| Risk Level | low |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, financial-statements, sec-filing
Related Tickers: QTRX
TL;DR
Quanterix filed an 8-K on Jan 14, 2025, updating on financials. No major news yet.
AI Summary
On January 14, 2025, Quanterix Corporation filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or significant events were detailed in the provided excerpt.
Why It Matters
This filing indicates Quanterix is providing updates on its financial performance and condition to the SEC, which is important for investors to monitor the company's health.
Risk Assessment
Risk Level: low — The filing is a standard procedural update and does not contain information that inherently increases or decreases risk.
Key Players & Entities
- Quanterix Corporation (company) — Registrant
- January 14, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Billerica, MA (location) — Principal executive offices
FAQ
What specific financial information is being reported in this 8-K filing?
The filing indicates it concerns 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but the provided excerpt does not detail specific figures.
When was the earliest event reported in this filing?
The earliest event reported was on January 14, 2025.
What is Quanterix Corporation's state of incorporation?
Quanterix Corporation is incorporated in Delaware.
Where are Quanterix Corporation's principal executive offices located?
Quanterix Corporation's principal executive offices are located at 900 Middlesex Turnpike, Billerica, MA 01821.
Is this filing intended to satisfy any other reporting obligations under the Securities Act?
The filing notes it may simultaneously satisfy the reporting obligation under Rule 425 of the Securities Act (17 CFR 230.425) if indicated by a checkbox, which is marked as 'true' in the provided text.
Filing Stats: 1,855 words · 7 min read · ~6 pages · Grade level 17.3 · Accepted 2025-01-14 07:02:42
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share QTRX The Nasdaq Glo
Filing Documents
- qtrx-20250114.htm (8-K) — 34KB
- qtrx01142025ex991.htm (EX-99.1) — 27KB
- 0001503274-25-000006.txt ( ) — 193KB
- qtrx-20250114.xsd (EX-101.SCH) — 2KB
- qtrx-20250114_lab.xml (EX-101.LAB) — 21KB
- qtrx-20250114_pre.xml (EX-101.PRE) — 12KB
- qtrx-20250114_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On January 14, 2025, Quanterix Corporation (the "Company" or "Quanterix") issued a press release (the "Press Release") containing selected preliminary, unaudited financial information for the fourth quarter and year ended December 31, 2024 (the "Preliminary Financial Information"). A copy of the Press Release is furnished as Exhibit 99.1 and is incorporated herein by reference. The Preliminary Financial Information is unaudited and preliminary and does not present all information necessary for an understanding of the Company's financial condition as of December 31, 2024 and its results of operations for the quarter and year ended December 31, 2024. This Preliminary Financial Information is subject to completion of the Company's normal quarter and year-end close procedures. These procedures, and the audit of the Company's financial statements for the year ended December 31, 2024, are ongoing and could result in changes to the Preliminary Financial Information. The information in this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing. IMPORTANT ADDITIONAL INFORMATION In connection with the proposed acquisition of Akoya Biosciences, Inc. ("Akoya") by Quanterix, Quanterix will file with the U.S. Securities and Exchange Commission (the "SEC") a registration statement on Form S-4 (the "Registration Statement"), which will contain a joint proxy statement of Quanterix and Akoya and a prospectus of Quanterix (the "Joint Proxy Statement/Prospectus"), and each of Quanterix and Akoya may file with the SEC other relevant documents regarding the proposed transaction. INVESTORS AND SE
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated January 14, 2025 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. QUANTERIX CORPORATION By: /s/ Vandana Sriram Vandana Sriram Chief Financial Officer Date: January 14, 2025